265 related articles for article (PubMed ID: 35563502)
1. Quantitative Systems Pharmacology and Biased Agonism at Opioid Receptors: A Potential Avenue for Improved Analgesics.
Bedini A; Cuna E; Baiula M; Spampinato S
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563502
[TBL] [Abstract][Full Text] [Related]
2. An updated assessment of the translational promise of G-protein-biased kappa opioid receptor agonists to treat pain and other indications without debilitating adverse effects.
French AR; van Rijn RM
Pharmacol Res; 2022 Mar; 177():106091. PubMed ID: 35101565
[TBL] [Abstract][Full Text] [Related]
3. A Novel G Protein-Biased Agonist at the
Conibear AE; Asghar J; Hill R; Henderson G; Borbely E; Tekus V; Helyes Z; Palandri J; Bailey C; Starke I; von Mentzer B; Kendall D; Kelly E
J Pharmacol Exp Ther; 2020 Feb; 372(2):224-236. PubMed ID: 31594792
[TBL] [Abstract][Full Text] [Related]
4. Signaling diversity of mu- and delta- opioid receptor ligands: Re-evaluating the benefits of β-arrestin/G protein signaling bias.
Pineyro G; Nagi K
Cell Signal; 2021 Apr; 80():109906. PubMed ID: 33383156
[TBL] [Abstract][Full Text] [Related]
5. The Quest for More Effective Analgesics with Reduced Abuse Liability and Fewer Adverse Effects: Promises, Pitfalls, and Future Perspectives of Biased Agonists at Opioid Receptors.
Bedini A
Methods Mol Biol; 2021; 2201():181-192. PubMed ID: 32975799
[TBL] [Abstract][Full Text] [Related]
6. Critical Assessment of G Protein-Biased Agonism at the μ-Opioid Receptor.
Gillis A; Kliewer A; Kelly E; Henderson G; Christie MJ; Schulz S; Canals M
Trends Pharmacol Sci; 2020 Dec; 41(12):947-959. PubMed ID: 33097283
[TBL] [Abstract][Full Text] [Related]
7. Mu Opioids Induce Biased Signaling at the Full-Length Seven Transmembrane C-Terminal Splice Variants of the mu Opioid Receptor Gene, Oprm1.
Narayan A; Hunkele A; Xu J; Bassoni DL; Pasternak GW; Pan YX
Cell Mol Neurobiol; 2021 Jul; 41(5):1059-1074. PubMed ID: 33033993
[TBL] [Abstract][Full Text] [Related]
8. A Biased View of
Conibear AE; Kelly E
Mol Pharmacol; 2019 Nov; 96(5):542-549. PubMed ID: 31175184
[TBL] [Abstract][Full Text] [Related]
9. Usefulness for the combination of G-protein- and β-arrestin-biased ligands of μ-opioid receptors: Prevention of antinociceptive tolerance.
Mori T; Kuzumaki N; Arima T; Narita M; Tateishi R; Kondo T; Hamada Y; Kuwata H; Kawata M; Yamazaki M; Sugita K; Matsuzawa A; Baba K; Yamauchi T; Higashiyama K; Nonaka M; Miyano K; Uezono Y; Narita M
Mol Pain; 2017; 13():1744806917740030. PubMed ID: 29056067
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo activity of cyclopeptide Dmt-c[d-Lys-Phe-Asp]NH
Gach-Janczak K; Piekielna-Ciesielska J; Adamska-Bartłomiejczyk A; Wtorek K; Ferrari F; Calo' G; Szymaszkiewicz A; Piasecka-Zelga J; Janecka A
Peptides; 2018 Jul; 105():51-57. PubMed ID: 29684591
[TBL] [Abstract][Full Text] [Related]
11. Biased versus Partial Agonism in the Search for Safer Opioid Analgesics.
Azevedo Neto J; Costanzini A; De Giorgio R; Lambert DG; Ruzza C; Calò G
Molecules; 2020 Aug; 25(17):. PubMed ID: 32854452
[TBL] [Abstract][Full Text] [Related]
12. Assessment of structure-activity relationships and biased agonism at the Mu opioid receptor of novel synthetic opioids using a novel, stable bio-assay platform.
Vasudevan L; Vandeputte M; Deventer M; Wouters E; Cannaert A; Stove CP
Biochem Pharmacol; 2020 Jul; 177():113910. PubMed ID: 32179045
[TBL] [Abstract][Full Text] [Related]
13. Noribogaine is a G-protein biased κ-opioid receptor agonist.
Maillet EL; Milon N; Heghinian MD; Fishback J; Schürer SC; Garamszegi N; Mash DC
Neuropharmacology; 2015 Dec; 99():675-88. PubMed ID: 26302653
[TBL] [Abstract][Full Text] [Related]
14. Influence of G protein-biased agonists of μ-opioid receptor on addiction-related behaviors.
Kudla L; Przewlocki R
Pharmacol Rep; 2021 Aug; 73(4):1033-1051. PubMed ID: 33835467
[TBL] [Abstract][Full Text] [Related]
15. G protein signaling-biased mu opioid receptor agonists that produce sustained G protein activation are noncompetitive agonists.
Stahl EL; Schmid CL; Acevedo-Canabal A; Read C; Grim TW; Kennedy NM; Bannister TD; Bohn LM
Proc Natl Acad Sci U S A; 2021 Nov; 118(48):. PubMed ID: 34819362
[TBL] [Abstract][Full Text] [Related]
16. A comprehensive review of partial opioid agonists for the treatment of chronic pain.
Gress K; Charipova K; Jung JW; Kaye AD; Paladini A; Varrassi G; Viswanath O; Urits I
Best Pract Res Clin Anaesthesiol; 2020 Sep; 34(3):449-461. PubMed ID: 33004158
[TBL] [Abstract][Full Text] [Related]
17. Biased Agonism as an Emerging Strategy in the Search for Better Opioid Analgesics.
Piekielna-Ciesielska J; Wtorek K; Janecka A
Curr Med Chem; 2020; 27(9):1562-1575. PubMed ID: 31057099
[TBL] [Abstract][Full Text] [Related]
18. Opioid signaling and design of analgesics.
Paul B; Sribhashyam S; Majumdar S
Prog Mol Biol Transl Sci; 2023; 195():153-176. PubMed ID: 36707153
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Intracellular Signaling Activities of κ-Opioid Receptor Agonists, Nalfurafine Analogs; Focusing on the Selectivity of G-Protein- and β-Arrestin-Mediated Pathways.
Yamaguchi M; Miyano K; Hirayama S; Karasawa Y; Ohshima K; Uezono E; Komatsu A; Nonaka M; Fujii H; Yamaguchi K; Iseki M; Hayashida M; Uezono Y
Molecules; 2022 Oct; 27(20):. PubMed ID: 36296658
[TBL] [Abstract][Full Text] [Related]
20. Structure-Based Evolution of G Protein-Biased μ-Opioid Receptor Agonists.
Wang H; Hetzer F; Huang W; Qu Q; Meyerowitz J; Kaindl J; Hübner H; Skiniotis G; Kobilka BK; Gmeiner P
Angew Chem Int Ed Engl; 2022 Jun; 61(26):e202200269. PubMed ID: 35385593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
